• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

High-throughput sequencing detection and ensartinib treatment of lung cancer harboring NTRK1 fusion.

作者信息

Song Zhengbo, Xu Chunwei, Pu Xingxiang, Zhu Youcai, Wang Wenxian, Li Xingliang, Gao Yanqiu, Zhu Wenliang, He Yunwei, Wu Lin, Mao Li, Chen Li, Chen Ming

机构信息

Department of Medical Oncology, Institute of Cancer and Basic Medicine, Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, Zhejiang, 310002, P. R. China.

Department of Pathology, Fujian Cancer Hospital, Fuzhou, Fujian, 350014, P. R. China.

出版信息

Cancer Commun (Lond). 2021 Feb;41(2):192-196. doi: 10.1002/cac2.12133. Epub 2021 Jan 16.

DOI:10.1002/cac2.12133
PMID:33452864
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7896745/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3c0d/7896745/253a136752d5/CAC2-41-192-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3c0d/7896745/253a136752d5/CAC2-41-192-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3c0d/7896745/253a136752d5/CAC2-41-192-g001.jpg

相似文献

1
High-throughput sequencing detection and ensartinib treatment of lung cancer harboring NTRK1 fusion.携带NTRK1融合的肺癌的高通量测序检测及恩沙替尼治疗
Cancer Commun (Lond). 2021 Feb;41(2):192-196. doi: 10.1002/cac2.12133. Epub 2021 Jan 16.
2
Ensartinib (X-396) a novel drug for anaplastic lymphoma kinase-positive non-small cell lung cancer patients: we need smart trials to avoid wasting good bullets.恩沙替尼（X-396）：一种用于间变性淋巴瘤激酶阳性非小细胞肺癌患者的新型药物——我们需要明智的试验以避免浪费好药。
Chin Clin Oncol. 2019 Oct;8(S1):S1. doi: 10.21037/cco.2018.09.03. Epub 2018 Oct 15.
3
[Pharmacology and Clinical Evaluation of Ensartinib Hydrochloride Capsule].[盐酸恩沙替尼胶囊的药理作用及临床评价]
Zhongguo Fei Ai Za Zhi. 2020 Aug 20;23(8):719-729. doi: 10.3779/j.issn.1009-3419.2020.102.34.
4
Ensartinib (X-396): what does it add for patients with ALK-rearranged NSCLC.恩沙替尼（X-396）：对ALK重排的非小细胞肺癌患者有何额外益处。
Chin Clin Oncol. 2019 Oct;8(S1):S4. doi: 10.21037/cco.2018.10.12. Epub 2018 Nov 9.
5
Background and rationale of the eXalt3 trial investigating X-396 in the treatment of ALK+ non-small-cell lung cancer.背景与理由的 eXalt3 试验研究 X-396 的治疗中的 ALK + 非小细胞肺癌。
Future Oncol. 2018 Aug;14(18):1781-1787. doi: 10.2217/fon-2017-0619. Epub 2018 Mar 6.
6
Durable Clinical Response to Crizotinib in IRF2BP2-NTRK1 Non-small-cell Lung Cancer.克唑替尼对IRF2BP2-NTRK1非小细胞肺癌的持久临床反应
Clin Lung Cancer. 2019 May;20(3):e233-e237. doi: 10.1016/j.cllc.2018.12.017. Epub 2018 Dec 31.
7
Inserting Ensartinib Into the Starting Lineup for ALK-Rearranged Lung Cancer-A Likely Limited Role on a Deep Bench.将恩沙替尼纳入ALK重排肺癌的初始治疗方案——在众多选择中作用可能有限
JAMA Oncol. 2021 Nov 1;7(11):1615-1616. doi: 10.1001/jamaoncol.2021.3369.
8
Mass balance, metabolic disposition, and pharmacokinetics of [C]ensartinib, a novel potent anaplastic lymphoma kinase (ALK) inhibitor, in healthy subjects following oral administration.健康受试者口服新型强效间变性淋巴瘤激酶（ALK）抑制剂[C]ensartinib 的物质平衡、代谢分布和药代动力学。
Cancer Chemother Pharmacol. 2020 Dec;86(6):719-730. doi: 10.1007/s00280-020-04159-0. Epub 2020 Oct 12.
9
Effects and mechanism of ensartinib (X-396) on the adhesion and metastasis of non-small cell lung cancer cells.恩莎替尼（X-396）对非小细胞肺癌细胞黏附与转移的影响及机制
Pharmazie. 2019 Sep 1;74(9):543-546. doi: 10.1691/ph.2019.9461.
10
Efficacy, safety, and biomarker analysis of ensartinib in crizotinib-resistant, ALK-positive non-small-cell lung cancer: a multicentre, phase 2 trial.恩沙替尼治疗克唑替尼耐药、ALK 阳性非小细胞肺癌的疗效、安全性和生物标志物分析：一项多中心、Ⅱ期临床试验。
Lancet Respir Med. 2020 Jan;8(1):45-53. doi: 10.1016/S2213-2600(19)30252-8. Epub 2019 Oct 15.

引用本文的文献

1
Survival benefit of combinatorial osimertinib rechallenge and entrectinib in an EGFR-mutant NSCLC patient with acquired LMNA-NTRK1 fusion following osimertinib resistance.奥希替尼耐药后，联合使用奥希替尼再挑战和恩曲替尼对一名获得性LMNA-NTRK1融合的EGFR突变非小细胞肺癌患者的生存获益。
Respirol Case Rep. 2022 Oct 17;10(11):e01054. doi: 10.1002/rcr2.1054. eCollection 2022 Nov.
2
Expert consensus on the diagnosis and treatment of NTRK gene fusion solid tumors in China.中国 NTRK 基因融合型实体瘤诊断与治疗专家共识。
Thorac Cancer. 2022 Nov;13(21):3084-3097. doi: 10.1111/1759-7714.14644. Epub 2022 Sep 20.

本文引用的文献

1
Simultaneous Detection of Gene Fusions and Base Mutations in Cancer Tissue Biopsies by Sequencing Dual Nucleic Acid Templates in Unified Reaction.通过在统一反应中对双链核酸模板进行测序，实现癌症组织活检中基因融合和碱基突变的同时检测。
Clin Chem. 2020 Jan 1;66(1):178-187. doi: 10.1373/clinchem.2019.308833.
2
Detection of Fusions: Merits and Limitations of Current Diagnostic Platforms.融合基因检测：当前诊断平台的优缺点。
Cancer Res. 2019 Jul 1;79(13):3163-3168. doi: 10.1158/0008-5472.CAN-19-0372. Epub 2019 Jun 13.
3
Detection of Tumor NTRK Gene Fusions to Identify Patients Who May Benefit from Tyrosine Kinase (TRK) Inhibitor Therapy.
检测肿瘤 NTRK 基因融合，以确定可能从酪氨酸激酶（TRK）抑制剂治疗中获益的患者。
J Mol Diagn. 2019 Jul;21(4):553-571. doi: 10.1016/j.jmoldx.2019.03.008. Epub 2019 May 7.
4
Durable Clinical Response to Crizotinib in IRF2BP2-NTRK1 Non-small-cell Lung Cancer.克唑替尼对IRF2BP2-NTRK1非小细胞肺癌的持久临床反应
Clin Lung Cancer. 2019 May;20(3):e233-e237. doi: 10.1016/j.cllc.2018.12.017. Epub 2018 Dec 31.
5
Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical Trial.纳武利尤单抗对比多西他赛用于经治的晚期 NSCLC 中国患者人群：CheckMate 078 随机 III 期临床研究。
J Thorac Oncol. 2019 May;14(5):867-875. doi: 10.1016/j.jtho.2019.01.006. Epub 2019 Jan 17.
6
Entrectinib Effective across Fusion-Positive Cancers.恩曲替尼对多种融合阳性癌症有效。
Cancer Discov. 2019 Jan;9(1):OF4. doi: 10.1158/2159-8290.CD-NB2018-156. Epub 2018 Nov 27.
7
Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations.Repotrectinib（TPX-0005）是一种下一代 ROS1/TRK/ALK 抑制剂，能够强力抑制 ROS1/TRK/ALK 溶剂前沿突变。
Cancer Discov. 2018 Oct;8(10):1227-1236. doi: 10.1158/2159-8290.CD-18-0484. Epub 2018 Aug 9.
8
Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.拉罗替尼在成人和儿童TRK融合阳性癌症中的疗效。
N Engl J Med. 2018 Feb 22;378(8):731-739. doi: 10.1056/NEJMoa1714448.
9
Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer.恩曲替尼治疗 NTRK1 重排非小细胞肺癌的持久临床应答。
J Thorac Oncol. 2015 Dec;10(12):1670-4. doi: 10.1097/01.JTO.0000473485.38553.f0.
10
Comprehensive investigation of oncogenic driver mutations in Chinese non-small cell lung cancer patients.中国非小细胞肺癌患者致癌驱动基因突变的综合研究。
Oncotarget. 2015 Oct 27;6(33):34300-8. doi: 10.18632/oncotarget.5549.